We're unable to sign you in at this time. Please try again in a few minutes.
We were able to sign you in, but your subscription(s) could not be found. Please try again in a few minutes.
There may be a problem with your account. Please contact the AMA Service Center to resolve this issue.
Contact the AMA Service Center:
Telephone: 1 (800) 262-2350 or 1 (312) 670-7827  *   Email: subscriptions@jamanetwork.com
Error Message ......
Article |

Study of Bisphosphonates Leads to New Views of Bone Remodeling, Therapy for Skeletal Malignancy

Charles Marwick
JAMA. 1997;278(10):803-804. doi:10.1001/jama.1997.03550100025010.
Text Size: A A A
Published online


CHEMICAL compounds called bisphosphonates, some of which were originally used as water softeners, are playing an increasing role in the treatment of metastatic skeletal malignancies. The development may provide new insights into the normal processes involved in bone remodeling.

Some solid tumors, especially those of the breast, prostate, and lung, readily metastasize to bone, where they stimulate its formation or, more frequently, its destruction. Since bisphosphonates inhibit bone turnover by decreasing bone resorption, investigators have become interested in studying their possible use for controlling or even preventing metastatic skeletal lesions.

"We've been remiss in not considering this specific problem of bone metastasis. We need to understand it to develop rational ways of preventing and treating it. The information is now available or is on the horizon which can really make a difference in this process," said Gregory Mundy, MD, introducing a symposium last month at the National Institutes of Health


Sign in

Purchase Options

• Buy this article
• Subscribe to the journal
• Rent this article ?




Also Meets CME requirements for:
Browse CME for all U.S. States
Accreditation Information
The American Medical Association is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. The AMA designates this journal-based CME activity for a maximum of 1 AMA PRA Category 1 CreditTM per course. Physicians should claim only the credit commensurate with the extent of their participation in the activity. Physicians who complete the CME course and score at least 80% correct on the quiz are eligible for AMA PRA Category 1 CreditTM.
Note: You must get at least of the answers correct to pass this quiz.
Please click the checkbox indicating that you have read the full article in order to submit your answers.
Your answers have been saved for later.
You have not filled in all the answers to complete this quiz
The following questions were not answered:
Sorry, you have unsuccessfully completed this CME quiz with a score of
The following questions were not answered correctly:
Commitment to Change (optional):
Indicate what change(s) you will implement in your practice, if any, based on this CME course.
Your quiz results:
The filled radio buttons indicate your responses. The preferred responses are highlighted
For CME Course: A Proposed Model for Initial Assessment and Management of Acute Heart Failure Syndromes
Indicate what changes(s) you will implement in your practice, if any, based on this CME course.


Some tools below are only available to our subscribers or users with an online account.

0 Citations

Sign in

Purchase Options

• Buy this article
• Subscribe to the journal
• Rent this article ?

Related Content

Customize your page view by dragging & repositioning the boxes below.